. 2023 Oct;149(13):11025-11030.

doi: 10.1007/s00432-023-04995-6. Epub 2023 Jun 19.

SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia

Fang Cheng^#^{1

2}, Hang Xiang^#³, Robert Peter Gale⁴, Siyi Chen⁵, Jiao Qu⁶, Hao Guo⁷, Qiubai Li^{8

9}, Yanli Zhang¹⁰, Weiming Li¹¹

Affiliations

¹ Department of Pharmacy, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China.
² Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, 430022, China.
³ Department of Hematology, The Ventral Hospital of Enshi Tujia and Miao Autonomous Prefecture, Yichang, 443000, China.
⁴ Centre for Haematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, UK.
⁵ Department of Rheumatology and Immunology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China.
⁶ Department of Hematology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China.
⁷ Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450000, Henan, China.
⁸ Department of Rheumatology and Immunology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China. qiubaili@hust.edu.cn.
⁹ Hubei Engineering Research Center for Application of Extracellular Vesicles, Hubei University of Science and Technology, Xianning, China. qiubaili@hust.edu.cn.
¹⁰ Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450000, Henan, China. 13203729690@163.com.
¹¹ Department of Hematology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China. lee937@126.com.

^# Contributed equally.

PMID: 37337067
PMCID: PMC11797113
DOI: 10.1007/s00432-023-04995-6

SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia

Fang Cheng et al. J Cancer Res Clin Oncol. 2023 Oct.

. 2023 Oct;149(13):11025-11030.

doi: 10.1007/s00432-023-04995-6. Epub 2023 Jun 19.

Authors

Fang Cheng^#^{1

2}, Hang Xiang^#³, Robert Peter Gale⁴, Siyi Chen⁵, Jiao Qu⁶, Hao Guo⁷, Qiubai Li^{8

9}, Yanli Zhang¹⁰, Weiming Li¹¹

Affiliations

¹ Department of Pharmacy, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China.
² Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, 430022, China.
³ Department of Hematology, The Ventral Hospital of Enshi Tujia and Miao Autonomous Prefecture, Yichang, 443000, China.
⁴ Centre for Haematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, UK.
⁵ Department of Rheumatology and Immunology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China.
⁶ Department of Hematology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China.
⁷ Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450000, Henan, China.
⁸ Department of Rheumatology and Immunology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China. qiubaili@hust.edu.cn.
⁹ Hubei Engineering Research Center for Application of Extracellular Vesicles, Hubei University of Science and Technology, Xianning, China. qiubaili@hust.edu.cn.
¹⁰ Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450000, Henan, China. 13203729690@163.com.
¹¹ Department of Hematology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China. lee937@126.com.

^# Contributed equally.

PMID: 37337067
PMCID: PMC11797113
DOI: 10.1007/s00432-023-04995-6

Abstract

Objective: A SARS-CoV-2 Omicron (BA.5.2) epidemic began in China in December, 2022 following stopping the zero COVID policy.

Methods: We studied features of the epidemic in 1,121 persons with chronic myeloid leukaemia (CML).

Results: 1103 (98%) were in chronic, 10 in accelerated and 8 in acute phases. 834 (74%) became infected almost all of whom met criteria for COVID-19. The most common symptoms were fever (91%), cough (90%) and fatigue (82%). 42 infected persons were asymptomatic. Most people quarantined at home and self-medicated. 22 were hospitalized for COVID-19. At admission 5 had mild, 14, moderate and 3, severe/critical disease according to World Health Organization (WHO) criteria. 5 received respiratory assistance, 3 were admitted to the intensive care unit (ICU) and 1 in accelerated phase died from COVID-19. Co-variates associated with a risk of COVID-19 in SARS-CoV-2-infected subjects include age ≥ 65 years, higher education level and imatinib therapy.

Conclusion: In conclusion, most SARS-CoV-2 Omicron BA.5.2 infections in persons with CML resulted in COVID-19 most of which cases are mild with only 1 death.

Keywords: COVID-19; Chronic myeloid leukaemia; Omicron BA.5.2; SARS-CoV-2 Omicron.

PubMed Disclaimer

Conflict of interest statement

RPG is a consultant to Antengene Biotech LLC, Ascentage Pharma Group and NexImmune Inc.; Medical Director, FFF Enterprises Inc.; Board of Directors: Russian Foundation for Cancer Research Support; and Scientific Advisory Boards, Nanexa AB and StemRad Ltd.

Figures

See this image and copyright information in PMC

Cited by

DNA binding, and apoptosis-inducing activities of a β-ionone-derived ester in human myeloid leukemia cells: multispectral and molecular dynamic simulation analyses.
Jahanbakhsh K, Ansari-Ahl R, Mashhadi B, Zare M, Samarkhazan NS, Kazemzadeh H, Dehghan G, Dehkordi MF, Gharaghani S, Mahdavi M. Jahanbakhsh K, et al. Sci Rep. 2024 Nov 14;14(1):27985. doi: 10.1038/s41598-024-78690-y. Sci Rep. 2024. PMID: 39543249 Free PMC article.
Management of chronic myelogenous leukemia with COVID-19 and hepatitis B.
Yu T, Li W, Yu T. Yu T, et al. Front Oncol. 2023 Aug 3;13:1217023. doi: 10.3389/fonc.2023.1217023. eCollection 2023. Front Oncol. 2023. PMID: 37601670 Free PMC article. Review.
Inactivated vaccine dosage and serum IgG levels correlate with persistent COVID-19 infections in hematologic malignancy patients during the Omicron Surge in China.
Ye L, Yang Y, Zhang X, Wang L, Zhu L, Li X, Zhou Y, Zheng X, Zhou X, Ren Y, Ma L, Xu G, Yang C, Wang H, Zhou D, Yang M, Ye X, Wei J, Yu W, Qian J, Lou Y, Xie W, Huang J, Meng H, Jin J, Tong H. Ye L, et al. BMC Infect Dis. 2024 Oct 11;24(1):1141. doi: 10.1186/s12879-024-10063-2. BMC Infect Dis. 2024. PMID: 39394593 Free PMC article.

References

1. Banerjee S, Yadav S, Banerjee S, Fakayode SO, Parvathareddy J, Reichard W et al (2021) Drug repurposing to identify nilotinib as a potential SARS-CoV-2 main protease inhibitor: insights from a computational and in vitro study. J Chem Inf Model 61(11):5469–5483. 10.1021/acs.jcim.1c00524 - PMC - PubMed
1. Başcı S, Ata N, Altuntaş F, Yiğenoğlu TN, Dal MS, Korkmaz S et al (2020) Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm Pract 26(7):1676–1682. 10.1177/1078155220953198 - PMC - PubMed
1. Breccia M, Abruzzese E, Accurso V, Attolico I, Barulli S, Bergamaschi M et al (2022) COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. Br J Haematol 196(3):559–565. 10.1111/bjh.17890 - PMC - PubMed
1. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J et al (2014) Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 58(8):4885–4893. 10.1128/aac.03036-14 - PMC - PubMed
1. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966–984. 10.1038/s41375-020-0776-2 - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- PubMed Central
- Springer
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia

Affiliations

SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous